|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
However, the role of C14ORF166 in the development and progression of cancer remains largely unknown.
|
26219895 |
2016 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
However, the role of c14orf166 in human cancer remains unclear.
|
25964093 |
2015 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
C14orf166 (chromosome 14 open reading frame 166) plays a crucial role in some tumors, but its role in bladder cancer hasn't been explored.
|
26905879 |
2016 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
The chi-square test indicated that high-level expression of C14ORF166 was significantly associated with International Federation of Gynecology and Obstetrics (FIGO) stage (P < 0.001), vital status (P = 0.026), tumor size (P = 0.034), serum squamous cell carcinoma antigen level (SCC-Ag; P = 0.035), and pelvic lymph node metastasis (P < 0.001).
|
26219895 |
2016 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
However, the role of C14ORF166 in the development and progression of cancer remains largely unknown.
|
26219895 |
2016 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
However, the role of c14orf166 in human cancer remains unclear.
|
25964093 |
2015 |
|
Autoimmune Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Systemic lupus erythematosus (SLE) is a complex autoimmune disease in which 70% of patients experience disfiguring skin inflammation (grouped under the rubric of cutaneous lupus erythematosus [CLE]).
|
30745462 |
2019 |
|
Brain Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Moreover, CGI-99 was highly expressed in all brain tumors which is in agreement with the Northern blot analysis.
|
15147888 |
2004 |
|
Lung Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Multiple blinded raters validated CLE videos of lung tumours and mediastinal nodes twice.EUS-nCLE-FNA was performed in 22 patients with suspected or proven lung cancer in whom 27 lesions (six tumours, 21 mediastinal nodes) were evaluated without complications.
|
31023849 |
2019 |
|
Dermatologic disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Our results demonstrate that ruxolitinib significantly decreases the production of CLE-typical cytokines (CXCL10, CXCL9, MxA) and might be a promising drug for future clinical studies in patients with CLE and related autoimmune skin diseases.
|
27892610 |
2017 |
|
Caffeine related disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Two epithelial cell lines, HCLE and HK2, have both higher concentrations of GLUT1 and increased basal 2DG uptake (3-4 fold) compared to L929 cells, and subsequently display greater maximal inhibition by caffeine (66-70%).
|
28322926 |
2017 |
|
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Importantly, delivery of the IL-6-receptor humanized monoclonal antibody tocilizumab robustly abrogates CGI-99-induced metastasis in vivo.
|
28166202 |
2017 |
|
Neoplasm Metastasis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
High expression of c14orf166 (cutoff score >6) was significantly associated with gender (P = 0.016), clinical stage (P = 0.010), T classification (P = 0.013), N classification (P = 0.029), distant metastasis (P < 0.001), vital status (P = 0.001), and treatment method (P = 0.028; chi-square test).
|
25964093 |
2015 |
|
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
LHGDN |
For the first time, c14orf166 was identified asa novel metastasis-associated protein, and the roles of radixin, moesin and c14orf166 in cancer metastasis deserve further investigations.
|
19152423 |
2009 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Taken together, we have isolated a novel protein CGI-99, which may be involved in the functional regulation of human ninein in the centrosome structure and may also be important in brain development and tumorigenesis.
|
15147888 |
2004 |
|
Carcinogenesis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
C14orf166, a 28 kD protein regulating RNA transcription and translation, may serve a critical role in oncogenesis.
|
28000881 |
2017 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Chromosome 14 ORF 166 (C14orf166), a protein involved in the regulation of RNA transcription and translation, has been reported to possess the potency to promote tumorigenesis; however, the role of C14orf166 in non-small-cell lung cancer (NSCLC) remains unknown.
|
30126850 |
2018 |
|
Tumor Progression
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
C14orf166 overexpression correlates with tumor progression and poor prognosis of breast cancer.
|
26883017 |
2016 |
|
Endotoxemia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Our findings reveal novel mechanisms by which polyphenolic extracts from ABE, LGE and especially CLE target the gut-liver axis to protect diet-induced obese mice against metabolic endotoxaemia, insulin resistance and hepatic steatosis, which importantly improves hepatic insulin clearance.
|
29270816 |
2018 |
|
Secondary malignant neoplasm of lymph node
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The chi-square test indicated that high-level expression of C14ORF166 was significantly associated with International Federation of Gynecology and Obstetrics (FIGO) stage (P < 0.001), vital status (P = 0.026), tumor size (P = 0.034), serum squamous cell carcinoma antigen level (SCC-Ag; P = 0.035), and pelvic lymph node metastasis (P < 0.001).
|
26219895 |
2016 |
|
Secondary malignant neoplasm of lymph node
|
0.040 |
Biomarker
|
disease |
BEFREE |
Multivariate analysis revealed c14orf166 was an independent prognostic indicator of OS and DFS in all patients (P = 0.046, P = 0.006) and was associated with poor OS and DFS in the subgroups with advanced clinical stage (P = 0.037, P = 0.001), lymph node metastasis (P = 0.001, P < 0.001), and T3-T4 disease (P = 0.005, P = 0.001), respectively.
|
25964093 |
2015 |
|
Secondary malignant neoplasm of lymph node
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
There was a significant difference in T stage, lymph node metastasis and TNM stage in patients categorized according to different C14orf166 expression levels.
|
28000881 |
2017 |
|
Secondary malignant neoplasm of lymph node
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
High expression of C14orf166 was significantly associated with the T stage (<i>P</i>=0.006), lymph node metastasis (<i>P</i>=0.001), advanced TNM stage (<i>P</i><0.001), and chemotherapy (<i>P</i><0.001).
|
30126850 |
2018 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
CLE-10 from <i>Carpesium abrotanoides</i> L. Suppresses the Growth of Human Breast Cancer Cells (MDA-MB-231) In Vitro by Inducing Apoptosis and Pro-Death Autophagy Via the PI3K/Akt/mTOR Signaling Pathway.
|
30897708 |
2019 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
C14orf166 overexpression promoted breast cancer cell proliferation, whereas knockdown of C14orf166 inhibited this effect.
|
26883017 |
2016 |